

13<sup>th</sup> March 2012

Circular No. P07/2012

Dear Healthcare Professional,

**Re: Supply shortage of Vfend (voriconazole)**

Vfend (voriconazole) is a Pfizer product which has been authorised in the EU since 19 March 2002 and is marketed in Malta as 50mg and 200mg tablets. The Medicines Authority has been notified of a supply problem with this product, mainly affecting the solution for infusion and to a lesser extent the tablet form. This shortage in supply is a result of technical issues at a manufacturing site however there are no concerns over the quality and safety of Vfend currently available on the market. The local agents VJ Salamone have been contacted and they have confirmed that this shortage will not be affecting the supply of tablets in Malta.

The [question and answer document](#) issued by the EMA is available. Suspected Adverse Drug Reactions may be reported using the Medicines Authority yellow card scheme or online at <http://www.medicinesauthority.gov.mt/pub/adr.doc> or to the marketing authorisation holder or their local representatives.

*Healthcare professionals are encouraged to regularly check the Medicines Authority website for product safety updates as these are issued on an ongoing basis.*